Combination therapies have emerged as the standard of care in many diseases including oncology. It is widely accepted that the biological pathways fundamental in many serious diseases are highly complex with individual cell types containing a unique network of pathways and, as a result, traditional monotherapies are often insufficient.
With a decade of experience analysing over 10 million unique drug combinations, we are recognized as the leader in drug combination screening. Partner with us and gain access to our deep combination screening expertise, proprietary HT combination drug screening platform and Chalice™ bioinformatics software to discover new combination therapies and aid patient stratification.
How Can Horizon’s Combination Drug Screening Platform Work for You?
We have spent more than a decade designing and refining our automated platform and proprietary Chalice software. With our platform you can profile your compounds as single agents or combinations across hundreds of well annotated cancer cell lines, and gain actionable insights in a short period of time.
Our HT combination screening platform operates by using sophisticated bioinformatics tools, which can assess drug or compound combinations over a defined range to look for synergistic or antagonistic effects. These may be observed either as an increase in the anti-proliferative or cell killing effect, or as potency shift such that lower dosages are required to see the same therapeutic effect.
|Combination effects can manifest as efficacy boosts (orange line) or potency shifts (blue line)|
Once the effect of each compound as a single agent is removed, an Excess Matrix is generated that provides a simple visual representation of information about combination activity at the multiple concentrations and ratios of the two drugs and where synergies or antagonism can be seen.
Watching our recent webinar to learn more about our drug combination screening platform.
Our Cell Line Collection
Why Work with Horizon Discovery?
|ATL313, A Potent, and Selective A2A Agonist as a Novel Drug Candidate for the Treatment of Multiple Myeloma||Poster|
|Identification of Combinatorial Drugs that Synergistically Kill Both Eribulin-Sensitive and Eribulin-Insensitive Tumor Cells||Paper|
|Pharmacogenomic Investigation of Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765): Drug Sensitivity in Diffuse Large B-Cell Lymphoma (DLBCL) Within a Tumor Microenvironment–Aligned High-Throughput Screen||Poster|